Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee

Executive Summary

FDA seems content to negotiate a user fee for biosimilars in a manner that typifies the composition of the products: similar, but not the same, as the other user fee programs.
Advertisement

Related Content

Biosimilar User Fee Negotiations Hit Snag With GPhA Gambit For Lower Fees
Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say
Biosimilars: Eight Is More Than Enough For FDA
Biosimilars Pathway Dilemma: When Should Sponsors Pick (k) Before (a)?
FDA Could Face 13% Funding Cut Under House FY '12 Appropriations Bill
FDA “Busy” With Biosimilars; Sponsors Already In Pre-IND Meetings
Early Birds Get FDA Worrying: How To Handle Quick Biosimilar Applications?
Generic User Fee Negotiators Struggling To Meet June Deadline
PDUFA V: Final Recommendations Fund Proposals In Two Of Three Tiers
PDUFA V: Final Recommendations Fund Proposals In Two Of Three Tiers

Topics

Advertisement
UsernamePublicRestriction

Register

PS053390

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel